HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $21 Price Target
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $21 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $21 price target.
